Gary Goldenberg, MD, reviewed recent and upcoming studies and treatment options in dermatology for different diseases, such as acne, psoriasis, and atopic dermatitis, in his session, “Therapeutic Hotline,” on the third day of Fall Clinical 2022.

He started off with acne vulgaris and mentioned, “There’s a triple-combination product not available yet,” along with data and photos showing success. For acne, he summarized the following treatments:

• Triple-combination clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% for pediatric patients with acne
• Tazarotene 0.045% lotion for truncal acne
• Tazarotene foam 0.1% for acne vulgaris in patients aged 12 years and older
• Clascoterone cream 1%
• Tretinoin and benzoyl peroxide cream 0.1%/3%
• Aviclear laser for treatment of mild, moderate, and severe acne
• Photopneumatic acne therapy system for treatment of mild to moderate acne
• Oral sarecycline
• Over the counter acne regimen of 2% salicylic acid cleanser and 2% salicylic acid spot treatment

Dr Goldberg moved on to rosacea, noting, “5% microencapsulated benzoyl peroxide cream for the treatment of the inflammatory lesions of rosacea.”

For eczema/atopic dermatitis, he discussed abrocitinib and upadacitinib, along with the following treatment options:

• Tapinarof cream 1% once daily for the treatment of extensive atopic dermatitis in adolescents and children
• Ruxolitinib cream 1.5% , a topical JAK inhibitor approved for atopic dermatitis
• Tralokinumab, an IL-13 antibody for atopic dermatitis
• Lebrikizumab, coming soon for the treatment of moderate to severe atopic dermatitis across body regions
• Nemolizumab, coming soon looking specifically at dose-ranging study
• Oral difelikefalin, showing efficacy for itch in atopic dermatitis and currently approved for uremic pruritus
• Topical cannabinoids, potential for cannabidiols as therapeutics in dermatology

Next, Dr Goldenberg discussed new studies and treatment options for psoriasis. He touched upon the following drugs and treatment methods:

• Tapinarof cream 1% once daily, recently approved for the treatment of plaque psoriasis
• Roflumilast cream, approved for the treatment of psoriasis
• Calcipotriene and betamethasone dipropionate, a new topical for psoriasis
• Halobetasol propionate and tazarotene lotion 0.01%/0.045% for difficult to treat psoriasis and TNF-a mechanism of action
• Apremilast
• Certolozumab
• Ixekizumab  
• Secukinumab
• Guselkumab
• Tildrakizumab
• Risankizumab
• Brodalumab
• Imsidolimab, new drug for generalized pustular psoriasis
• Deucravacitinib, now approved
• Targeted phototherapy
• Mind.px, precision medication

Dr Goldenberg also discussed other diseases and their available treatment options:

• Seborrheic dermatitis – roflumilast foam 0.3%
• Prurigo nodularis – nemolizumab
• Hidradenitis suppurativa – secukinumab
• Vitiligo – ruxolitinib cream
• Actinic keratosis – tirbanibulin
• Melanoma and skin cancer detection/prognosis
  • Electrical impedance spectroscopy
  • Pigmented lesion assay
  • SRT-100 superficial radiation therapy
• Alopecia areata – baricitinib, ritlecitinib
• Cosmeceuticals – Melaclear Advanced

Reference
Goldenberg G. Therapeutic hotline. Presented at: Fall Clinical Dermatology Conference 2022; October 20–23, 2022; Las Vegas, NV.